the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
Published 1 year ago • 86 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:04
ibrutinib monotherapy in wm: long-term follow-up data
-
4:14
long-term safety and efficacy of sutimlimab for chronic itp
-
2:14
single agent ibrutinib produces long-term disease control in waldenström’s: the pivotal trial
-
1:15
the safety and efficacy of peritransplantation ruxolitinib in patients with mf
-
2:36
safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with r/r myeloma
-
1:34
long-term surveillance for cardiac toxicities in patients with hl treated with chemotherapy
-
3:27
the safety and efficacy of acalabrutinib for the treatment of r/r mzl
-
19:06
lab safety
-
55:26
immune checkpoint inhibitor cardiotoxicity
-
22:52
haematological emergencies
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:25
the safety & efficacy of copanlisib nivolumab in patients with rt and tnhl: a chemo-free approach
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
2:15
safety and efficacy of astx727 in patients with cmml from phase ii and phase iii ascertain studies
-
1:34
innovate study update: long-term pfs in wm
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:16
predictors of long-term survival in patients with dlbcl/hgbcl following autosct
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
3:17
estimating transfusion-related medical costs & time burden in patients with mf in simplify-1